Ubrogepant

25 interactions 1 explained in plain English
Also sold as: Ubrelvy Ubrelvy®
About Ubrogepant

Ubrogepant is a calcitonin gene-related peptide receptor antagonist used to treat migraine headache symptoms. Read the full Ubrogepant drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Asciminib Capmatinib Olutasidenib Mitapivat Lenacapavir Injection
1 Contraindicated 23 Major 1 Moderate
All (25) Contraindicated (1) Major (23) Moderate (1)

Contraindicated

Ubrogepant Ketoconazole Topical Extina® Foam Increased ubrogepant exposure Details

Major

Ubrogepant Asciminib Scemblix Increased BCRP substrate exposure and an increased risk of BCRP substrate-related adverse effects Details Ubrogepant Capmatinib Tabrecta Risk of increased adverse reactions Details Ubrogepant Cyclosporine Injection Atopica Increased ubrogepant exposure Details Ubrogepant Cyclosporine Ophthalmic Cequa Increased ubrogepant exposure Details Ubrogepant Darolutamide Nubeqa Increased ubrogepant exposure Details Ubrogepant Dexamethasone Injection Decadron Decreased ubrogepant exposure Details Ubrogepant Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Decreased ubrogepant exposure Details Ubrogepant Elacestrant Orserdu Increased ubrogepant exposure Details Ubrogepant Enasidenib Idhifa Increased ubrogepant exposure Details Ubrogepant Encorafenib Braftovi Altered (increased or reduced) ubrogepant exposure, an increased risk of ubrogepant-related toxicities and reduced efficacy of ubr... Details Ubrogepant Febuxostat Uloric Increased ubrogepant exposure Details Ubrogepant Fostamatinib Tavalisse Increased ubrogepant exposure Details Ubrogepant Fostemsavir Rukobia Increased ubrogepant exposure Details Ubrogepant Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Ubrogepant Lenacapavir Injection Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Ubrogepant Lenacapavir Oral Sunlenca Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Ubrogepant Leniolisib Joenja Increased BCRP substrate exposure Details Ubrogepant Letermovir Injection Prevymis Increased ubrogepant exposure and risk of toxicity Details Ubrogepant Midostaurin Rydapt Increased BCRP substrate exposure Details Ubrogepant Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Ubrogepant Nafcillin Injection Unipen® Injection Decreased ubrogepant exposure Details Ubrogepant Nevirapine Viramune Decreased ubrogepant exposure Details Ubrogepant Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details

Moderate

Ubrogepant Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.